Our systematic review demonstrates that GLP-1 receptor agonists (GLP-1 RAs), including semaglutide, liraglutide, tirzepatide, and exenatide, offer sustained efficacy in weight management, with consistent improvements in glycemic control among patients with obesity or overweight. This evidence concerns the gene GLP1R and obesity disorder.